Immatics (IMTX) Gains from Investment Securities (2020 - 2025)
Immatics (IMTX) reported Gains from Investment Securities of -$150550.6 for Q2 2025, down 121.57% on a YoY basis from $697823.1 in Q2 2024, and up 91.04% sequentially from -$1.7 million in Q1 2025.
Immatics (IMTX) Gains from Investment Securities (2020 - 2025) Analysis & Trends
Immatics (IMTX) has 6 years of Gains from Investment Securities data on file, last reported at -$150550.6 in Q2 2025.
- For the quarter ending Q2 2025, Gains from Investment Securities fell 121.57% year-over-year to -$150550.6; the trailing twelve-month figure through Dec 2025 stood at -$1.8 million (up 90.15% YoY), and the FY2025 full-year result was -$2.0 million, up 89.54% from the prior year.
- Gains from Investment Securities advanced to -$150550.6 in Q2 2025, from -$1.7 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $14.3 million in Q2 2023 to a low of -$18.5 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of $273636.3 in 2024 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities plunged 1365.71% in 2022 and soared 380.2% in 2023, its largest moves.
- Tracing IMTX's Gains from Investment Securities over 5 years: stood at $1.8 million in 2021, then plunged by 270.8% to -$3.1 million in 2022, then tumbled by 144.09% to -$7.6 million in 2023, then plunged by 82.33% to -$13.9 million in 2024, then surged by 98.92% to -$150550.6 in 2025.
- Business Quant data shows IMTX's Gains from Investment Securities at -$150550.6 in Q2 2025, -$1.7 million in Q1 2025, and -$13.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Immatics | 1.08 Bn | 533.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -150,550.64 |
| Jun 30, 2025 | -150,550.64 |
| Mar 31, 2025 | -1.68 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | -13.93 Mn |
| Dec 31, 2024 | -13.93 Mn |
| Sep 30, 2024 | -4.21 Mn |
| Sep 30, 2024 | -4.21 Mn |
| Jun 30, 2024 | 697,823.15 |
| Jun 30, 2024 | 697,823.15 |
| Mar 31, 2024 | -1.13 Mn |
| Mar 31, 2024 | -1.13 Mn |
| Dec 31, 2023 | -7.64 Mn |
| Dec 31, 2023 | -7.64 Mn |
| Sep 30, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.52 Mn |
| Jun 30, 2023 | 14.27 Mn |
| Jun 30, 2023 | 14.27 Mn |
| Mar 31, 2023 | -7.94 Mn |
| Mar 31, 2023 | -7.94 Mn |